About Respiree
Respiree is a medical technology company that has developed a comprehensive cardio-pulmonary remote patient monitoring platform designed to transform healthcare delivery across the care continuum. The company's flagship solutions include Respiree Care, an end-to-end enterprise-connected remote care platform, and Respiree 1Bio, a decentralized clinical trials platform integrating over 1000 pulmonary-cardio multi-modal biomarkers. Respiree's technology enables early deterioration detection with greater than 90% accuracy, providing healthcare systems with days of advance warning. The platform features cellular hubs for ease in remote data acquisition, comprehensive lung-cardio biomarker insights, and seamless software integration with enterprise and EHR systems. The solution includes customizable feedback and alert systems designed to reduce hospital readmissions and healthcare costs. The company serves multiple healthcare segments including hospital-at-home programs, chronic disease management, rehabilitation services, and pharmaceutical companies conducting decentralized clinical trials. Respiree's platform is US FDA 510(k) cleared, CE approved, and holds approvals from Australia's Therapeutic Goods Administration (TGA). The company maintains rigorous compliance standards including HIPAA certification, FDA cybersecurity certification, ISO 13485 QMS certification, and ISO 27001:2022 certification. Respiree is trusted by leading healthcare systems, medical technology companies, biopharma organizations, and patients globally.
Clinical Focus
Medical conditions and clinical areas addressed by Respiree.
Who It Serves
Milestones & Awards
Recent Milestones
President's Technology Award 2024, Featured at ATS 2022 RIS, Falling Walls Finalist 2022, Top 50 Southeast Asia Health Tech Startup 2022, HealthTech 250 Most Promising Early-stage Ventures 2022
Awards & Recognition
President's Technology Award 2024, ATS 2022 RIS Featured Start-up, Falling Walls Finalist 2022, Top 50 Southeast Asia Health Tech Startup in 2022, HealthTech 250 - Most promising Early-stage Ventures in 2022
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 63 →
Acurable
Acurable creates accurate and user-friendly wearable medical devices for at-home monitoring of sleep apnea, epilepsy, COPD, and asthma.
Aktiia
Aktiia develops optical blood pressure monitoring technology integrated into wearable devices for continuous, cuffless blood pressure tracking. The company focuses on enabling remote patient monitoring and hypertension management through clinically validated wearable solutions.
August Health
August Health provides an AI-enabled EHR platform designed specifically for senior living communities. The platform includes integrated modules for electronic health records, medication management (eMAR), move-ins, billing, care tracking, and predictive analytics to help operators shift from reactive to proactive care strategies.
Babyscripts
Babyscripts is a market-leading digital maternity care platform that combines remote patient monitoring, care management, and patient engagement tools to improve maternal health outcomes across prenatal and postpartum care for health systems, payers, and private practices.
Belun Technology Company
11-50 employees
Belun Technology develops FDA-cleared AI-powered wearable ring technology for sleep apnea diagnosis and continuous health monitoring. The company provides medical-grade sleep diagnostics that bridge the gap between home and hospital care.
Binah.ai
Binah.ai provides an AI-powered, video-based, 100% software solution that enables measurement of vital signs and health indicators using smartphone or tablet cameras. In 35 seconds, users can measure vital signs, chronic disease risks, stress levels, and bloodless blood tests without wearables or equipment.
Biobeat
Biobeat develops FDA-cleared cuffless ambulatory blood pressure monitoring (ABPM) solutions using a wireless, non-invasive chest patch. The company enables 24-hour hypertension monitoring for cardiologists, nephrologists, and hypertension centers to improve diagnosis accuracy and treatment management.
Biofourmis
growth · 350 employees
Biofourmis provides a connected technology platform that partners with health systems, hospitals, and payers to revolutionize care delivery across the continuum.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.